Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended | ||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Revenue | $ 13,293 | $ 6,261 | $ 36,207 | $ 14,086 | $ 15,652 | $ 11,565 | ||
| Operating expenses: | ||||||||
| Cost of revenues | 18,529 | 17,140 | 54,882 | 51,363 | 51,489 | 26,282 | ||
| Selling, general and administrative expenses | 870,053 | 836,215 | 3,225,753 | 3,308,227 | 4,519,636 | 5,009,323 | ||
| Research and development expenses | 139,048 | 159,846 | 471,135 | 922,120 | 1,153,333 | 1,353,084 | ||
| Total costs and expenses | 1,027,630 | 1,013,201 | 3,751,770 | 4,281,710 | 5,724,458 | 6,388,689 | ||
| Loss from operations | (1,014,337) | (1,006,940) | (3,715,563) | (4,267,624) | (5,708,806) | (6,377,124) | ||
| Other (expense) income: | ||||||||
| Interest expense | (808,770) | (39,890) | (1,968,274) | (119,671) | (567,048) | (150,531) | ||
| Gain on extinguishment of derivative liabilities | 0 | 0 | $ 1,158,197 | $ (0) | 1,158,197 | 0 | ||
| Decrease to fair value of derivative | 0 | 0 | (0) | 1,000,000 | 0 | 1,000,000 | 1,000,000 | 108,944 |
| Total other income | (808,770) | (39,890) | (810,077) | 880,329 | 432,952 | 136,642 | ||
| Net loss | $ (1,823,107) | $ (1,046,830) | $ (4,525,640) | $ (3,387,295) | $ (4,525,640) | $ (3,387,295) | $ (5,275,854) | $ (6,240,482) |
| Loss per share - basic and diluted | ||||||||
| Net loss per common share - basic and diluted (in dollars per share) | $ (1.42) | $ (0.88) | $ (3.58) | $ (2.86) | $ (4.40) | $ (5.67) | ||
| Weighted common shares - basic and diluted (in shares) | 1,279,967 | 1,184,738 | 1,265,340 | 1,184,266 | 1,199,574 | 1,100,007 | ||
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|